USPTO serial 85547252
CONVERGIS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LAVACHE, LINDA M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CONVERGIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Veterinary preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; antibiotics for use in livestock; veterinary preparations for the treatment of enteric clostridium infections; veterinary preparations for the prevention of enteric clostridium infections; veterinary preparations in the treatment of Cushing's disease in animals; veterinary preparations for the control and symptomatic relief of viral and bacterial infectious diseases of cattle; immunorestorative biopharmaceutical for enhancing the immune system of cattle; veterinary preparations for controlling and destroying vermin, namely, insecticides and pesticides for use with poultry and livestock animals and poultry and livestock premises; veterinary preparations, namely, vaccines, antimicrobials and other medicinal drugs for the prevention, treatment, control, or symptomatic relief of infectious, non-infectious and metabolic diseases of poultry and livestock; animal feed supplements; medicated feed and water additives for animals; veterinary preparations for food safety, namely, anti-microbial preparations for inhibiting microbiological decomposition in food and animal feed; veterinary preparations, namely, anti-microbials and vaccines for food safety and food animal processing; antibacterial pharmaceuticals; veterinary preparations for production improvement for poultry and livestock, namely, medicated feed additives for poultry and livestock and medicated water additives for poultry and livestock; diagnostic agents, preparations and substances to identify pathogens or residues of biological interest for veterinary use; bactericides, namely, bacteriophage used as a human food safety agent to reduce levels of food borne pathogens carried on livestock or meat prior to being processed for human consumption; bacterial vector based vaccines relating to infection and non-infectious diseases or productivity loss in all avian, ruminant and swine species, the prevention or reduction of contamination of food produced by any or all avian, ruminant or swine species, the prevention of food-borne diseases in humans associated with contact with or consumption of food produced by any or all avian, ruminant or swine species; pathogen reduction preparations for pathogens that are in or on animals and that take the form of bacteria contaminants in meat which may be found in the livestock's digestive systems, or on the livestock during the harvest and processing phases; pathogen reduction treatment preparation for use in treating bacteria contaminants in meat which may be found in the livestock's digestive systems, or on the livestock during the harvest and processing phases; veterinary preparations containing natural plant extracts for oral administration to avian species and other livestock as an aid in managing health risks and productivity, namely, veterinary preparations for infection and non-infectious diseases or productivity loss in avian species and other livestock; Veterinary preparations for use in the treatment of fleas on pets; veterinary preparations for use in the prevention of fleas on pets; insecticides to prevent fleas on pets; transdermal drug delivery products for use on companion and food animals, namely, skin penetration medicine for pain and inflammation; veterinary preparations for companion animals in the treatment of parasitic infestations; transdermal topical solution administered by veterinarians in a surgical setting to treat pain in companion animals; veterinary preparations for companion animals in the treatment of anxiety, diabetes, hyperthyroidism, hypothyroidism, obesity, urine spraying, urinary incontinence; veterinary preparations for companion animals in the treatment of dental and oral disease, namely, stomatitis, Feline Odontoclastic Resorptive Lesion, periodontitis; veterinary preparations for companion animals in the treatment of chronic pain associated with osteoarthritis and cancer; veterinary preparations for companion animals in the treatment of gastrointestinal disorders associated with cholangiohepatitis, inflammatory bowel disorder, pancreatitis, gastritis, chronic colitis, enteritis; veterinary preparations for companion animals in the treatment of central nervous systems diseases and disorders, namely, cerebellar hypoplasia, cerebellar abiotrophy, laryngeal paralysis, meningoencephalitis, syringomyelia; veterinary preparations for companion animals in the treatment of neurological and neurodegenerative disorders, namely, seizure, epilepsy, neuropathies; veterinary preparations for companion animals in the treatment of parasitic infections and infestations associated with acaricides, heartworm, GI nematodes, mange, fleas; veterinary preparations for companion animals in the treatment of cardiovascular conditions, namely, hypertension, cardiomyopathies, heart murmurs, heart failure; veterinary preparations for companion animals in the treatment of dermatologic conditions, namely, canine atopic dermatitis, skin rash, flea allergy, food allergy, cancer; veterinary preparations for companion animals in the treatment of chronic kidney disease and associated conditions, namely, anemia, hyperphosphatemia, hypocalcemia, hypertension, cachexia; veterinary preparations for companion animals in the treatment of acute pain associated with orthopedic and soft tissue surgery, trauma, and musculoskeletal conditions; veterinary preparations for companion animals in the treatment of osteoarthritis, otitis and wound healing; veterinary preparations for companion animals in the treatment of upper respiratory infections; veterinary preparations for companion animals in the treatment of allergy atopic conditions associated with atopic dermatitis, seasonal allergies, asthma; veterinary preparations for companion animals in the treatment of liver disease, acute and chronic hepatitis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 19, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 18, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 11, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 10, 2015 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 22, 2015 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 22, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 23, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 22, 2014 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 11, 2014 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 11, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 12, 2014 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 10, 2014 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 10, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 5, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 4, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 24, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 3, 2013 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 3, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 11, 2013 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 11, 2013 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 11, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 18, 2012 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 23, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 23, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 3, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 17, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 15, 2012 | ALIE | ASSIGNED TO LIE | — |
| Sep 6, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 6, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 6, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 6, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 6, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 6, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 6, 2012 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Sep 4, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 4, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 4, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 1, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 31, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 31, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 28, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 28, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 28, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 27, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 23, 2012 | NWAP | NEW APPLICATION ENTERED | — |